Pfizer/BioNTech Updated Omicron Adapted COVID-19 Vaccine Shows 4-Fold Higher Neutralizing Activity

Pfizer Inc PFE and BioNTech SE BNTX announced updated data from a Phase 2/3 trial demonstrating a robust neutralizing immune response one month after a 30-µg booster dose of omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.
Immune responses against BA.4/BA.5 sublineages were substantially higher for those who received the bivalent vaccine compared to the companies' original COVID-19 vaccine, with a similar safety and tolerability profile between both vaccines.
These results reinforce the previously reported early clinical data measured seven days after a booster dose of the bivalent vaccine, as well as the preclinical data.
Related: Pfizer, BioNTech Launch Omicron-Adapted COVID Shot-Flu Combination Vaccine Study.
Among the overall study population, the omicron BA.4/BA.5-adapted bivalent vaccine showed a substantially higher increase in neutralizing antibody titers compared to pre-booster levels.
For individuals 18 to 55 years of age, the geometric mean titer was 606, representing a 9.5-fold rise from pre-booster levels.
For individuals older than 55 years, the GMT was 896, representing a 13.2-fold rise.
By contrast, participants over 55 who received a 30-µg booster dose of the companies' original COVID-19 vaccine had a GMT of 236, representing a 2.9-fold rise.
Price Action: BNTX shares are up 2.58% at $149.00, and PFE stock is up 0.72% at $46.90 on the last check Friday.
Photo Via Company